Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Insights from 2023 WCLC
A

WCLC 2023 Insights: "Association of TTF-1 Expression With Outcomes to IO & KRAS G12C Inhibition in Lung Adenocarcinoma"

By Insights from 2023 WCLC FEATURING Alessandro Di Federico
By Insights from 2023 WCLC FEATURING Alessandro Di Federico
88 views
October 17, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse
Lung
14:08

Risk of Hepatotoxicity From Sequential IO Followed by KRASG12C Targe…

Dana-Farber Cancer Institute

B. Ricciuti

228 views
29:32

Updates in KRAS G12C Mutant NSCLC: Demographics, Clinical Features, …

Dana-Farber Cancer Institute

B. Ricciuti

238 views
02:35

ESMO 2023 Insights: "Phase 2 KRYSTAL-7 Trial - Adagrasib+Pembro Comb…

ecancer

P. Janne

98 views
05:48

WCLC 2023 Insights: "Association of TTF-1 Expression With Outcomes t…

Insights from 2023 WCLC

A. Di Federico

88 views
09:08

WCLC 2023 Insights: "Mechanisms of Resistance to KRAS G12C Inhibitor…

Insights from 2023 WCLC

B. Ricciuti

98 views
09:57

WCLC 2023 Insights: "3-Year Outcomes & Correlative Analyses in Patie…

Insights from 2023 WCLC

B. Ricciuti

101 views
15:30

Small Cell Lung Cancer: A Brief Review of the Treatment Landscape

Dana-Farber Cancer Institute

J. Sands

611 views